Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

10,080 total articles

Roofing Reality Check: Risk Is Rising Even in Quiet Storm Years

Roofing Reality Check: Risk Is Rising Even in Quiet Storm Years

Verisk Analytics released its 2026 U.S. Roof Report showing that in 2025, average residential roof replacement costs rose 33% and repair costs climbed 25% compared to the prior four-year average, despite a nearly 20% decline in overall claims volume. The report cites frequent smaller hail events, aging roofs, and regional volatility as key drivers …

Genius Group Provides Response to Unusual Market Activity

Genius Group Provides Response to Unusual Market Activity

Genius Group Limited (NYSE American: GNS) issued a statement responding to an unusual spike in its share price and trading volume on May 27-28, 2026, confirming there are no undisclosed material developments to explain the activity. The company highlighted recent significant corporate initiatives including approval of an AI Treasury strategy target…

Talkspace Stockholders Vote to Approve Acquisition by UHS

Talkspace Stockholders Vote to Approve Acquisition by UHS

Talkspace, Inc., a leading virtual behavioral healthcare provider, announced that its stockholders have approved the acquisition by Universal Health Services (UHS). The merger is expected to complete in the third quarter of 2026 pending regulatory approvals and other customary closing conditions. The acquisition aims to expand access to high-qualit…

The Next Great AI Revolution May Be Drug Delivery

The Next Great AI Revolution May Be Drug Delivery

NeOnc Technologies Holdings (NASDAQ:NTHI) is gaining investor attention as it develops AI-enhanced delivery technologies aimed at overcoming challenges like the blood-brain barrier in treating aggressive brain cancers such as glioblastoma. Leveraging AI and precision medicine, NeOnc is positioned at the forefront of a shifting biotech paradigm focu…

Duluth Trading Co. Expands Online and In-Store “Garden Shop” with Protective Apparel and Durable Gear

Duluth Trading Co. Expands Online and In-Store “Garden Shop” with Protective Apparel and Durable Gear

Duluth Trading Co. has expanded and refreshed its Garden Shop both online and in over 60 retail stores, focusing on durable and functional gardening apparel and accessories for women and men. The refreshed collection includes best-selling Heirloom Gardening Bib Overalls for women with high customer ratings, new gardening pants, and an expanded men'…

BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development

BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development

BioNexus Gene Lab Corp. emphasized at the 2026 China–Malaysia Economic Cooperation Outlook Forum the shift in Malaysia-China biotech collaboration from mere trade to strategic co-development, clinical validation, and commercialization across ASEAN. The company highlights its role as an ASEAN hub for precision diagnostics, AI-driven healthcare data,…

SRx Health Solutions Invests in Uber Technologies, Inc. and Provides Shareholders with Portfolio Update

SRx Health Solutions Invests in Uber Technologies, Inc. and Provides Shareholders with Portfolio Update

SRx Health Solutions announced a new investment in Uber Technologies, Inc. as part of portfolio adjustments including reduced exposure to Compass, Inc. and Bitcoin, and adding hedges in select international markets. This repositioning comes in response to the EMJX stress model turning negative after a sustained bullish period, prompting a more caut…

Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment

Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment

Clearmind Medicine Inc., a clinical-stage biotech company, announced the filing of a Japanese patent application for its proprietary non-hallucinogenic psychedelic-based compound MEAI, designed for treating depression. This move expands Clearmind's intellectual property portfolio globally and aligns with its focus on neuroplastogen-derived therapeu…

Lianhe Sowell International Group Ltd. Announces Results of Extraordinary General Meeting of Shareholders on May 29, 2026

Lianhe Sowell International Group Ltd. Announces Results of Extraordinary General Meeting of Shareholders on May 29, 2026

Lianhe Sowell International Group Ltd., a Nasdaq-listed provider of industrial machine vision and robotics solutions, announced the approval of five key proposals at its extraordinary general meeting held on May 29, 2026. These include a 16-for-1 share consolidation, a significant increase in authorized share capital from $50,000 to $80 million, am…

Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia

Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia

Optimi Health Corp. acknowledged Australia's Therapeutic Goods Administration updated Authorized Prescriber framework, broadening therapist eligibility and treatment settings for psychedelic-assisted therapies using Optimi's MDMA and psilocybin products. These changes support scalable commercial growth as Australia leads globally in prescribed psyc…

Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits

Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits

Moleculin Biotech announced new data at ASCO 2026 demonstrating that Annamycin, their lead drug candidate, shows no detectable cardiotoxicity even at cumulative doses far exceeding conventional anthracycline limits. An independent review by Cleveland Clinic specialists supports a differentiated cardiac safety profile. The data bolster ongoing pivot…

SAIC Board of Directors Declares Cash Dividend

SAIC Board of Directors Declares Cash Dividend

Science Applications International Corp. (SAIC) announced a cash dividend of $0.37 per share payable on July 24, 2026, to shareholders of record as of July 10, 2026. SAIC intends to continue quarterly dividend payments, subject to board approval each quarter, based on earnings and financial condition. The company is a leading mission integrator spe…

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

SAB Biotherapeutics announced that it will present clinical data on SAB-142, its lead immunotherapy candidate for newly diagnosed Stage 3 type 1 diabetes, at the American Diabetes Association's 2026 Scientific Sessions and the Federation of Clinical Immunology Societies 2026 Annual Meeting. The presentations will showcase SAB-142's safety, pharmaco…